Amneal Agrees to Acquire Kashiv Biosciences to Create Global Biosimilar Leader; Reports Strong ...

Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader

PISCATAWAY, N.J.--(BUSINESS WIRE)--Apr 22, 2026-

Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance

– Acquisition Positions Amneal to Capitalize on $300B+ Global Biologics LOE Opportunity – – Transaction Accelerates Growth Profile and Diversification –...

Amneal Pharmaceuticals Moves to Acquire Kashiv BioSciences in $1.1B+ Deal to Dominate the Biosimilar Wave - Channelchek

Amneal Pharmaceuticals (Nasdaq: AMRX) announced on April 21 that it has entered into a definitive agreement to acquire 100% of Kashiv BioSciences, LLC in a transaction that could exceed $1.1 billion in total value — a strategic bet on one of the most significant inflection points in the pharmaceutical industry in decades. The deal structure includes $375 million in cash and $375 million in equity payable at closing, plus up to $350 million in po…

Kashiv BioSciences to be acquired by Amneal Pharmaceuticals

Kashiv BioSciences, LLC, announced that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. The transaction is subject to approval by Amneal shareholders, receipt of regulatory approvals and satisfaction of customary closing conditions. It is expected to close in the second half of 2026. This acquisition combines Kashiv’s extensive expertise in the development and manufacturing of biosimilars with Amneal’s s…

Amneal to acquire Kashiv BioSciences to create global biosimilar leader

BRIDGEWATER, N.J. – Amneal Pharmaceuticals announced Wednesday that it has entered into a definitive agreement to acquire 100% of Kashiv BioSciences. The transaction includes consideration of $375 million in cash and $375 million in equity payable at closing, along with up to $350 million in contingent payments tied to the achievement of specified regulatory milestones, potential royalties linked to commercial performance, and funding of Kashiv’…

Kashiv BioSciences Agrees to Be Acquired by Amneal ...